| Type | Public |
|---|---|
| Nasdaq: MACK Russell Microcap Index component | |
| Industry | Pharmaceuticals |
| Founded | 2000 in Cambridge, Massachusetts |
| Headquarters | , |
Number of employees | 426 (2016) |
| Website | www |
Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.
Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year.[1][2]
YouTube Encyclopedic
-
1/2Views:2 607305
-
2016 WMIF | Immunotherapy I: Checkpoint Activation and Cancer Vaccines
-
CYBR, TKMR, HCLP, QIHU - Harry Boxer, TheTechTrader.com
Transcription
History
Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.[3]
In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD.[3]
In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees.[4] In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University.[5]
In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion.[6]
On November 13, 2018, the statistical programming director Songjiang Wang, received "six months in prison and one year supervised released" after a guilty verdict was handed down to Wang from a United States District Judge in July 2018 for securities fraud and conspiracy to commit securities fraud.[7] Also on December 20, 2019, the United States Securities and Exchange Commission charged Wang with Insider trading.[8]
Pipeline
Merrimack has four drugs in clinical development.
- MM-302 – HER2 targeting antibody-drug conjugate
- MM-121 (seribantumab) – anti-HER3 monoclonal antibody
- MM-141 (istiratumab) – IGF-1R and HER3 bispecific monoclonal antibody
- MM-151 – anti-EGFR mixture of monoclonal antibody
References
- ^ "Investors - Merrimack".
- ^ "Onivyde pegylated liposomal EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 19 June 2020.
- ^ a b "Merrimack - Annual Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
- ^ Jamerson, Joshua (3 October 2016). "Merrimack Pharmaceuticals Cuts Jobs; CEO Resigns Amid Restructuring Effort". Wall Street Journal.
- ^ "Merrimack - Current Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
- ^ "Ipsen to buy some Merrimack assets for about $1 billion". Reuters. 9 January 2017.
- ^ "Former Biopharma Statistical Programmer Sentenced for Insider Trading". United States Department of Justice. November 13, 2018. Retrieved December 20, 2019.
- ^ "Former Biopharmaceutical Executive Charged with Insider Trading". U.S. Securities and Exchange Commission. December 20, 2019. Retrieved December 20, 2019.
This page was last edited on 23 August 2023, at 12:20